ERBB2 and neoplasm: From the results of the RPA, the genetic factors selected from the two-stage GWAS were more valuable when the analyses were stratified by tumor subtypes, and only one node of the genetic factors was statistically significant regardless of the clinical factors in HR- HER2- breast cancer.